Impact of clinical symptoms on interpretation of diagnostic assays for Clostridium difficile infections

Journal of Clinical Microbiology

Volumn 49, Issue 8, 2011, Pages 2887-2893

  Dubberke, Erik R ^a   Han, Zhuolin ^a   Bobo, Linda ^a   Hink, Tiffany ^a   Lawrence, Brenda ^b   Copper, Susan ^b   Hoppe Bauer, Joan ^b   Burnham, Carey Ann D ^a   Dunne Jr , William Michael ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BACTERIUM DETECTION; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIARRHEA; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FECES ANALYSIS; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEIC ACID AMPLIFICATION; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SYMPTOMATOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; FECES; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

CLOSTRIDIUM DIFFICILE;

EID: 79960951945     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00891-11     Document Type: Article

References (23)

1. Bobo, L., E. R. Dubberke, P. Tarr, and D. Haslam. 2010. Fecal activated protein kinase 2 elevation is significantly associated with human Clostridium difficile infection, abstr. 1415. Abstr. 48th Annu. Meet. Infect. Dis. Soc. Am. Infectious Diseases Society of America, Arlington, VA.
2. Chang, T. W., S. L. Gorbach, and J. B. Bartlett. 1978. Neutralization of Clostridium difficile toxin by Clostridium sordellii antitoxins. Infect. Immun. 22:418-422.
3. Cohen, S. H., et al. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect. Control Hosp. Epidemiol. 31:431-455.
4. Dubberke, E. R., et al. 2007. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin. Infect. Dis. 45:1543-1549.
5. Eastwood, K., P. Else, A. Charlett, and M. Wilcox. 2009. Comparison of nine commercially available Clostridium difficile toxin detection assays, a realtime PCR assay for C. difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. J. Clin. Microbiol. 47:3211-3217.
6. Fedorko, D. P., and E. C. Williams. 1997. Use of cycloserine-cefoxitin- fructose agar and L-proline-aminopeptidase (PRO Discs) in the rapid identification of Clostridium difficile. J. Clin. Microbiol. 35:1258-1259.
7. Han, Z., K. McMullen, S. M. Copper, D. K. Warren, and E. R. Dubberke. A Clostridium difficile infection "intervention:" change in toxin assay results in lower number of C. difficile infection cases without changes in patient outcomes. Am. J. Infect. Control, in press.
8. Johnson, S., et al. 1992. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole: a randomized, placebo-controlled trial. Ann. Intern. Med. 117:297-302.
9. Karre, T., L. Sloan, R. Patel, J. Mandrekar, and J. Rosenblatt. 2011. Comparison of two commercial molecular assays to a laboratory-developed molecular assay for diagnosis of Clostridium difficile infection. J. Clin. Microbiol. 49:725-727.
10. Kirkland, K. B., and J. M. Weinstein. 1999. Adverse effects of contact isolation. Lancet 354:1177-1178.
11. Kvach, E. J., D. Ferguson, P. F. Riska, and M. L. Landry. 2010. Comparison of BD GeneOhm Cdiff real-time PCR assay with a two-step algorithm and a toxin A/B enzyme-linked immunosorbent assay for diagnosis of toxigenic Clostridium difficile infection. J. Clin. Microbiol. 48:109-114.
12. Novak-Weekley, S. M., et al. 2010. Clostridium difficile testing in the clinical laboratory by use of multiple testing algorithms. J. Clin. Microbiol. 48:889-893.
13. Peterson, L. R., et al. 2007. Detection of toxigenic Clostridium difficile in stool samples by real-time PCR for the diagnosis of C. difficile-associated diarrhea. Clin. Infect. Dis. 45:1152-1160.
14. Peterson, L. R., and A. Robicsek. 2009. Does my patient have Clostridium difficile infection? Ann. Intern. Med. 151:176-179.
15. Planche, T., and M. Wilcox. 2011. Reference assays for Clostridium difficile infection: one or two gold standards? J. Clin. Pathol. 64:1-5.
16. Riggs, M. M., et al. 2007. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin. Infect. Dis. 45:992-998.
17. Saint, S., L. A. Higgins, B. K. Nallamothu, and C. Chenoweth. 2003. Do physicians examine patients in contact isolation less frequently? A brief report. Am. J. Infect. Control 31:354-356.
18. Samra, Z., A. Luzon, and J. Bishara. 2008. Evaluation of two rapid immunochromatography tests for the detection of Clostridium difficile toxins. Dig. Dis. Sci. 53:1876-1879.
19. She, R. C., R. J. Durrant, and C. A. Petti. 2009. Evaluation of enzyme immunoassays to detect Clostridium difficile toxin from anaerobic stool culture. Am. J. Clin. Pathol. 131:81-84.
20. Steiner, T. S., C. A. Flores, T. T. Pizarro, and R. L. Guerrant. 1997. Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis. Clin. Diagn. Lab. Immunol. 4:719-722.
21. Stelfox, H. T., D. W. Bates, and D. A. Redelmeier. 2003. Safety of patients isolated for infection control. JAMA 290:1899-1905.
22. Tenover, F. C., et al. 2010. Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches. J. Clin. Microbiol. 48:3719-3724.
23. Wilcox, M. H., T. Planche, F. C. Fang, and P. Gilligan. 2010. What is the current role of algorithmic approaches for diagnosis of Clostridium difficile infection? J. Clin. Microbiol. 48:4347-4353.